UK Update: The New Model Clinical Investigation Agreement and the ABHI Code of Business Practice
This article was originally published in RAJ Devices
Executive Summary
Two recent developments in the UK – the implementation in the National Health Service of a model Clinical Investigation Agreement (mCIA)1,2 and a new code of business practice by the Association of British Healthcare Industries3 – represent significant changes to the legal and regulatory landscape for medical devices. The experience of the pharmaceutical industry under the model Clinical Trial Agreement (mCTA)4 and with the code of practice of the ABHI’s pharmaceutical counterpart, the ABPI, provides useful guidance on how to comply with, and utilise, these new additions to the medical devices framework.
You may also be interested in...
Pharmaceuticals and Social Media: An Uneasy Marriage?
Despite being the fastest growing marketing medium for many industries, social media channels present major legal and regulatory concerns for the pharmaceutical sector. Until the US Food and Drug Administration produces some guidance in this area later this year, pharma companies entering the fray have much to think about, explains Tim Worden.
Pharma and social media: an uneasy marriage?
Despite being the fastest growing marketing medium for many industries, social media channels present major legal and regulatory concerns for the pharma sector. Until the US FDA produces some guidance in this area later this year, pharma companies wanting to enter the fray have much to contemplate, explains Tim Worden.